IDYA · IDEAYA Biosciences, Inc.

IDEAYA Biosciences reported Q1 FY2026 results reflecting sustained investment in its clinical pipeline, with collaboration revenue providing a partial offset to deepening losses. Revenue reached $6.6M, recognized as research and development services are performed under the Servier agreement for darovasertib ex-US rights. This topline supported ongoing operations but was dwarfed by operating expenses, resulting in an operating loss of -$108.5M, a 28.6% widening from -$84.4M in the prior-year quarter. The increased deficit stems from the company's commitment to advancing product candidates through preclinical and clinical studies, including contracts with third-party organizations for testing, manufacturing, and supply of materials.

Looking forward, IDEAYA will continue requiring capital to develop candidates and sustain operations, with plans subject to change. Expenses are recognized as goods are delivered or services performed, aligning with contracted progress. This positions the company to navigate clinical uncertainties while leveraging partnerships for revenue bridges.